Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01696669
Other study ID # GEIS-21
Secondary ID 2009-016027-62
Status Completed
Phase Phase 2
First received
Last updated
Start date March 30, 2010
Est. completion date January 18, 2018

Study information

Verified date July 2018
Source Grupo Espanol de Investigacion en Sarcomas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Tumors of the Ewing sarcoma family (ES) affect children, adolescents and young adults. The reported incidence is 0.6 cases per million inhabitants every year. The peak incidence occurs between 10 and 20 years and it is rarely diagnosed beyond 30. The ES is a severe disease with a progression-free survival after 5 years of 60% in cases without metastasis and deadly in the majority of patients presenting metastasis. The ES is considered a systemic disease because, despite receiving an adequate local treatment, over 90% of patients deaths occur due to disseminated disease. Combined therapy of surgery, radiotherapy and chemotherapy has led to an improvement in the prognosis, achieving a survival of about 60% in most series

The MSKCC P6 protocol was developed for the treatment of high risk ES. In 2003, Kolb et al. reported the MSKCC experience after a 4-years follow-up of 68 patients who had been included from 1990 to 2001. Following the MSKCC P6 protocol, a survival rate of 82% was achieved in patients without metastasis, superior to the achieved with less intensive protocols. Following the guidelines of the MSKCC P6 protocol, in 2002 we modified the treatment schedule to create the modified P6 protocol (MP6). GEIS intends to develop MP6 as a clinical trial, which could provide the following potential advantages about current treatments:

1. Lower total dose of alkylating agents.

2. Early cardioprotection with dexrazoxane.

3. Radiotherapy adjusted to the initial response.

4. Pilot trial with the combination of Gemcitabine + Docetaxel for high-risk patients.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date January 18, 2018
Est. primary completion date December 20, 2017
Accepts healthy volunteers No
Gender All
Age group N/A to 40 Years
Eligibility Inclusion Criteria:

- Patients with Ewing's Sarcoma in which the molecular analysis has been performed in one of the 2 reference laboratories of the study and the EWS gene rearrangement has been confirmed by RT-PCR in the Hospital Sant Joan de Déu de Barcelona, or by fluorescence in situ hybridization (FISH) in the Cancer Research Center of Salamanca.

- High-risk patients will be those patients with metastases, patients with primary tumor in pelvis or axial bones and patients with (micro) metastases in bone marrow detected by the molecular study. The remaining patients will be considered as standard risk. Lung nodules identified by CT-scan with diameter > 5 mm will be considered metastatic. Nodules = 5 mm will be biopsied.

- Age = 40 years.

- Adequate renal and hepatic function , defined as calculated creatinine clearance > 60 ml/min, creatinine, total bilirubin, AST and/or ALT < 1,5 times the upper limit of normal (ULN).

- Normal cardiac function defined by echocardiography, or ejection fraction = 55%.

- ECOG performance status 0 - 1 (Appendix VIII).

- Informed consent form signed by parents, guardians or the patient (if over 18 years), prior to the start of treatment.

- Patients of childbearing age (both men and women) must use effective contraceptive methods before study entry and during the realization of it. Effective contraceptive methods for both women and men should be extended to 6 months after stopping the treatment under study. Pregnancy must be excluded by urine test (negative pregnancy test) prior to the inclusion in the study.

Exclusion Criteria:

- Pregnancy or breastfeeding.

- Active infection or other severe concomitant diseases.

- Severe psychiatric conditions that make impossible to obtain the signed informed consent form or limit the treatment compliance.

- Concurrent treatment with other experimental drugs within 30 days prior to study entry.

- History of previous cancer diagnosed or treated in the past 5 years except basal cell carcinoma, cervical carcinoma in situ or superficial bladder cancer.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chemotherapy
Vincristine, 2 mg/m^2 IV bolus, day 1. Doxorubicin: 75 mg/m^2 per cycle, or 25 mg/m^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1). Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults. Cyclophosphamide: 2100 mg/m^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2. MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide. G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is = 750 mm^3/L. Ifosfamide: 1800 mg/m^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m^2 total maximum dose). Window phase in high-risk patients (21-days cycle): Gemcitabine: 1000 mg/m^2 IV, 90 minutes on day 1 and 8. Docetaxel 100 mg/m^2, 2-3 hour infusion on day 8.
Procedure:
Surgery
Surgical intervention aiming to completely resect the tumor with negative margins.
Radiation:
Radiotherapy
On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response <90%. Patients will receive radiotherapy 21 days after the completion of chemotherapy.

Locations

Country Name City State
Spain Hospital Clínic de Barcelona Barcelona
Spain Hospital de la Santa Creu i Sant Pau Barcelona
Spain Hospital Vall d'Hebron Barcelona
Spain Hospital Sant Joan de Déu Esplugues de Llobregat
Spain Institut Català d'Oncologia l'Hospitalet Hospitalet de Llobregat
Spain Hospital Universitario de Canarias La Laguna
Spain Hospital Ramón y Cajal Madrid
Spain Hospital Son Espases Palma de Mallorca
Spain Hospital Universitario Miguel Servet Zaragoza

Sponsors (1)

Lead Sponsor Collaborator
Grupo Espanol de Investigacion en Sarcomas

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival Assessment of the progression free survival in all the patients enrolled in the study 3 years after the completion of the treatment under study. Assessment of the progression free survival in all the patients enrolled in the study 3 years after the completion of the treatment under study.
Secondary Objective response rate (ORR) To assess the objective response rate to treatment (ORR) defined following EMEA criteria (CPMP/EWP/205/95/Rev.3/Corr.2) in high risk patients with Ewing's sarcoma treated with an early window phase of Gemcitabine + docetaxel (G + D). two months
Secondary Assessment of disease progression To assess the disease progression, aiming to reach an index of disease progression < 20% for high risk patients during the maintenance phase with Gemcitabine + Docetaxel. to reach an index of disease progression < 20% for high risk patients during the maintenance phase with Gemcitabine + Docetaxel.
Secondary evaluate the toxicity and tolerance to the treatment Gemcitabine + Docetaxel in high risk patients, and toxicity and tolerance of mP6 treatment in all patients. To evaluate the toxicity and tolerance to the treatment Gemcitabine + Docetaxel in high risk patients, and toxicity and tolerance of mP6 treatment in all patients. 12 months
Secondary Assessment of bone marrow condition. Molecular diagnosis and extension study of bone marrow in all patients included in the trial. Assessment of prognostic significance of the type of translocation and the molecular effect in the bone marrow. 24 months
Secondary Study the impact of patients treated with Cardioxane in cardioprotection Creation of a cohort of patients treated with anthracyclines at high doses and early cardioprotection with dexrazoxane (Cardioxane). Long-term study of cardioprotection in these patients compared with historical series from the P6 protocol that did not received cardioprotection. 6 months
See also
  Status Clinical Trial Phase
Withdrawn NCT01734863 - Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Phase 3
Completed NCT01674101 - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy N/A
Completed NCT02736565 - Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma Phase 1
Completed NCT00563680 - QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors Phase 2
Completed NCT00987636 - Study in Localized and Disseminated Ewing Sarcoma Phase 3
Terminated NCT00038142 - Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients Phase 2
Completed NCT02890758 - Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Phase 1
Completed NCT01583543 - Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma Phase 2
Terminated NCT01313884 - Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma Phase 2
Completed NCT00004853 - Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy Phase 1
Terminated NCT00568464 - Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT) Phase 2
Completed NCT00001686 - Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
Completed NCT00492141 - Aerosol L9-NC and Temozolomide in Ewing's Sarcoma Phase 1/Phase 2
Active, not recruiting NCT00541411 - Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma N/A
Completed NCT02063022 - Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Phase 3
Completed NCT01598454 - Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides Phase 1
Recruiting NCT03442465 - Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
Completed NCT02511132 - A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma Phase 2
Completed NCT00923650 - Informed Consent in Pediatric Cancer Trials N/A
Completed NCT01962103 - Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Phase 1/Phase 2